Veracyte Inc (VCYT)

Currency in USD
33.70
-0.98(-2.83%)
Real-time Data·
VCYT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
33.1133.71
52 wk Range
22.6150.71
Key Statistics
Prev. Close
34.68
Open
33.5
Day's Range
33.11-33.71
52 wk Range
22.61-50.71
Volume
31.06K
Average Volume (3m)
826.84K
1-Year Change
3.6604%
Book Value / Share
16.57
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VCYT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
47.50
Upside
+40.95%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings upwards for the upcoming period

Veracyte Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Veracyte Inc Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte Inc Earnings Call Summary for Q4/2025

  • Veracyte Q4 2025 EPS of $0.53 beat forecasts by 35.9%; revenue of $141M exceeded estimates by 6.17%, growing 19% year-over-year.
  • Non-GAAP gross margin improved to 75.1%, up 580 basis points from prior year, driven by operational efficiencies and platform optimization.
  • Afirma and Decipher platforms drove growth with increased test volumes; company generated $52.6M in operating cash flow during Q4.
  • Q1 2026 revenue guidance set at $130.59M; full-year EPS forecast ranges from $0.34 to $0.45 per quarter for upcoming periods.
  • Stock rose 0.08% to $35.7 post-earnings; CEO emphasized successful v2 transcriptome platform transition and continued investment in product development.
Last Updated: 25/02/2026, 22:52
Read Full Transcript

Compare VCYT to Peers and Sector

Metrics to compare
VCYT
Peers
Sector
Relationship
P/E Ratio
41.5x−3.7x−0.5x
PEG Ratio
0.25−0.150.00
Price/Book
2.1x2.6x2.6x
Price / LTM Sales
5.3x1.8x3.2x
Upside (Analyst Target)
41.3%89.2%51.4%
Fair Value Upside
Unlock16.1%8.5%Unlock

Analyst Ratings

9 Buy
2 Hold
1 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 47.50
(+40.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Sell37.00+10.25%48.00Maintain05/03/2026
Needham
Buy48.00+43.03%44.00Maintain26/02/2026
UBS
Buy48.00+43.03%-Maintain12/01/2026
Needham
Buy44.00+31.11%-Maintain12/01/2026
Leerink Partners
Buy50.00+48.99%-Maintain12/01/2026

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
0.53 / 0.39
Revenue / Forecast
140.60M / 132.43M
EPS Revisions
Last 90 days

People Also Watch

105.55
SATS
-4.79%
33.65
BLSH
-3.91%
25.52
BEAM
-7.00%
112.19
CRDO
-2.22%
6.32
DBI
-4.67%

FAQ

What Is the Veracyte Inc (VCYT) Share Price Today?

The Veracyte Inc stock price today is 33.70 USD.

What Stock Exchange Does Veracyte Inc (VCYT) Trade On?

Veracyte Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Veracyte Inc?

The stock symbol (also called a 'ticker') for Veracyte Inc is "VCYT."

What Is the Current Veracyte Inc Market Cap?

As of today, Veracyte Inc market cap is 2.76B USD.

What Is Veracyte Inc's (VCYT) Earnings Per Share (TTM)?

The Veracyte Inc EPS is currently 0.82 (Trailing Twelve Months).

When Is the Next Veracyte Inc Earnings Date?

Veracyte Inc's next earnings report will be released on 12/05/2026.

Is VCYT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Veracyte Inc moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Veracyte Inc Stock Split?

Veracyte Inc has split 0 times. (See the VCYT stock split history page for full effective split date and price information.)

How Many Employees Does Veracyte Inc Have?

Veracyte Inc has 755 employees.

What is the current trading status of Veracyte Inc (VCYT)?

As of 06/03/2026, Veracyte Inc (VCYT) is trading at a price of 33.70 USD, with a previous close of 34.68 USD. The stock has fluctuated within a day range of 33.11 USD to 33.71 USD, while its 52-week range spans from 22.61 USD to 50.71 USD.

What Is Veracyte Inc (VCYT) Price Target According to Analysts?

The average 12-month price target for Veracyte Inc is 47.50 USD, with a high estimate of 53 USD and a low estimate of 37 USD. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +40.95% Upside potential.

What Is the VCYT Premarket Price?

VCYT's last pre-market stock price is 33.30 USD. The pre-market share volume is 2,050.00, and the stock has decreased by -1.38, or -3.98%.

What Is the VCYT After Hours Price?

VCYT's last after hours stock price is 35.36 USD, the stock has decreased by 0.68, or 1.96%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.